A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva) in Combination With OSI-906 or Placebo in Chemonaive Patients With Advanced NSCLC With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene.

Trial Profile

A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva) in Combination With OSI-906 or Placebo in Chemonaive Patients With Advanced NSCLC With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2014

At a glance

  • Drugs Linsitinib (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 12 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Aug 2014 Planned End Date changed from 1 Jul 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 12 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top